Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. develops clinical-stage biotechnology programs for cancer and rare diseases. Company news centers on TARA-002, an investigational cell-based therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, including updates from the ADVANCED-2 trial in BCG-Unresponsive and BCG-Naïve NMIBC patient groups.
Recurring updates also cover IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving long-term parenteral support. Other company announcements include clinical-conference presentations, FDA designation updates, financial results, equity compensation grants under Nasdaq rules, and capital-raising activity tied to Protara's development-stage pipeline.
Protara Therapeutics (Nasdaq:TARA), a clinical-stage biotech developing therapies for cancer and rare diseases, will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on May 26, 2026 at 9:30 a.m. ET. The live webcast and a limited-time archive will be available in the Events and Presentations section of Protara’s investor relations website.
Protara Therapeutics (Nasdaq:TARA) will host a virtual investor webinar at 4:30 pm ET on Tuesday, May 19, 2026.
The event will cover lymphatic malformations, current treatment landscape, market opportunity and regulatory path for TARA-002, plus clinical data supporting its use. Access is via the company’s investor relations website, with a replay available for a limited time.
Protara Therapeutics (Nasdaq:TARA) reported updated 12‑month data from Cohort A of its Phase 2 ADVANCED‑2 trial of TARA‑002 in BCG‑Naïve non‑muscle invasive bladder cancer.
TARA‑002 showed a 72% complete response (CR) rate at any time, 67% at 6 months, and 55% at 12 months, with mostly Grade 1, transient adverse events and no Grade 3 or higher treatment‑related events reported.
Protara Therapeutics (Nasdaq:TARA) reported first quarter 2026 results and pipeline updates. Unrestricted cash, cash equivalents and marketable debt securities totaled $177.4 million as of March 31, 2026, which Protara expects will fund planned operations into 2028.
The company plans a BLA submission for TARA-002 in lymphatic malformations in 2H 2027, aims to complete enrollment of the BCG-unresponsive ADVANCED-2 cohort and initiate the ADVANCED-3 registrational NMIBC trial in 2H 2026, and expects interim Phase 3 THRIVE-3 data in 2H 2026.
Protara Therapeutics (Nasdaq: TARA) will present updated interim 12-month data from Cohort A of the Phase 2 ADVANCED-2 trial of TARA-002 in BCG‑naïve NMIBC patients at the AUA Annual Meeting, May 15–18, 2026.
Data cutoff is April 5, 2026 and includes results from 31 enrolled BCG‑naïve patients. A second poster will encore previously reported BCG‑unresponsive cohort data.
Protara Therapeutics (Nasdaq: TARA) reported interim ADVANCED-2 data showing TARA-002 CR rates of 68.2% at six months (BCG-Unresponsive) and 66.7% at six months (BCG-Naïve) as of Jan 28, 2026. The company received FDA Breakthrough and Fast Track designations for TARA-002 in lymphatic malformations and expects multiple 2026 readouts. Cash, cash equivalents and investments were approximately $197.9 million at Dec 31, 2025, supporting operations into 2028.
Protara Therapeutics (Nasdaq: TARA) reported interim Phase 2 ADVANCED-2 results for intravesical TARA-002 in high-risk NMIBC cohorts as of Jan 28, 2026.
Key highlights: BCG-Unresponsive cohort six-month CR 68.2% (15/22) and any-time CR 65.7% (23/35); BCG-Naïve any-time CR 72.4% (21/29). No Grade 3+ treatment-related adverse events; enrollment for the BCG-Unresponsive registrational cohort expected to complete in 2H 2026.
Protara Therapeutics (Nasdaq: TARA) said management will present at two investor conferences in late February and early March 2026.
Virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference is scheduled for Feb 26, 2026 at 2:40 PM ET, and an in-person fireside chat at TD Cowen 46th Annual Health Care Conference is scheduled for Mar 3, 2026 at 2:30 PM ET in Boston. Live webcasts and limited-time archives are available via the company’s Events and Presentations webpage.
Protara Therapeutics (Nasdaq: TARA) granted inducement equity awards to a newly hired employee under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved 10,200 stock options (exercise price $7.04) granted on Feb 2, 2026 and 5,100 RSUs with a grant date of Apr 1, 2026.
Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years in three equal annual installments, subject to continued service.
Protara Therapeutics (NASDAQ: TARA) will present updated interim data from the Phase 2 ADVANCED-2 trial of TARA-002 at the ASCO Genitourinary Cancers Symposium in San Francisco, Feb 26–28, 2026.
The poster will report safety and efficacy from approximately 25 six-month evaluable BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients in Cohort B. ADVANCED-2 (NCT05951179) is an open-label Phase 2 study of intravesical TARA-002 with Cohort B (BCG-unresponsive, N=75–100) and Cohort A (BCG-naïve, N=31). Dosing: six weekly induction instillations (with optional reinduction) followed by three weekly maintenance instillations every three months.
Poster details: F15 (interim efficacy/safety in BCG-unresponsive) and H8 (interim safety/tolerability across cohorts), both scheduled for Poster Session B on Friday, Feb 27, 2026.